Artivion, Inc. (AORT) stock analysis

Healthcare · Medical Devices

From the 10-K filed 2026-02-18

How it makes money

Artivion earns revenue by selling specialized medical devices and preservation services for cardiac and vascular surgeries to treat aortic disease.

The company operates through two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment generates revenue from sales of aortic stent grafts, surgical sealants such as BioGlue, On-X mechanical heart valves, and other related surgical products. The Preservation Services segment generates revenue from the preservation of cardiac and vascular implantable human tissues.

Annual revenues reached $441.3 million for the year ended December 31, 2025, representing a 14% increase over the prior year. This revenue growth was driven primarily by higher sales volumes across aortic stent grafts, On-X products, and surgical sealants, which offset decreases in other product lines and preservation services.

What protects it: the moat

Management claims competitive advantages through intellectual property, regulatory approvals, and proprietary tissue processing, though many competitors possess greater financial and personnel resources.

The company faces competition from numerous domestic and international medical device, pharmaceutical, and biopharmaceutical companies, as well as for-profit and non-profit tissue processors. Management asserts that its competitive position relies on its ability to develop innovative technologies, secure regulatory clearances from the FDA and foreign regulators, obtain patent protection, and maintain established relationships with cardiac and vascular surgeons.

However, the filing notes that many current and potential competitors maintain greater financial and personnel resources, more extensive experience in clinical trials and regulatory processes, superior manufacturing efficiency, and larger contracts with hospital groups.

What growth costs

The filing does not detail specific ongoing capital expenditure figures for maintaining or expanding manufacturing, processing, and distribution infrastructure.

The company pursues growth through product development, regulatory approvals for new indications, global expansion into international territories, and business development including select acquisitions, licensing, and distribution agreements. The text outlines strategic initiatives in these areas but does not disclose specific financial allocations required to maintain or expand physical plants, equipment, or R&D.

What could damage it

Unfavorable international regulatory developments and government pricing restrictions can impose substantial financial liabilities and erode operating profit margins over time.

The company operates extensively outside the United States, exposing it to complex regulatory frameworks, government-set pricing, and long collection cycles, particularly where customers are government-funded hospitals. For example, Italian authorities assessed overpayments for medical devices between 2015 and 2018, leading to negotiated settlements, while potential repayment exposure for the 2019 through 2025 period is estimated at approximately $2.3 million. Similar retroactive assessments or strict pricing caps in other international jurisdictions could impair financial condition and cash flows.

About Artivion, Inc.

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system; E-xtra Design Engineering, a range of stent graft systems for the treatment of aortic vascular diseases, such as TAAA and Artivex; E-nside, a multibranch stent graft system; E-tegra, an AAA stent graft system; E-ventus BX and Tuva BX balloon-expandable peripheral stent grafts; and E-liac, a stent graft used to treat aneurysmal iliac arteries. In addition, the company offers synthetic vascular grafts that are used in open aortic and peripheral vascular surgical procedures; BioGlue, a surgical sealant; CryoValve SG pulmonary heart valve; CryoPatch SG pulmonary cardiac patch; SynerGraft, a decellularization technology; vascular preservation services; and PhotoFix, a bovine pericardial patch fixated. It markets its products and preservation services primarily to physicians through a direct sales team to hospitals and other healthcare facilities. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

Other companies in Medical Devices